Absorption, Distribution, Metabolism, and Excretion of Revefenacin, a Long-Acting Muscarinic Antagonist (LAMA), in Healthy Male Subjects

被引：0

作者：

Bourdet, D. ^{[1
]}

Yeola, S. ^{[1
]}

Colson, P. ^{[1
]}

Pendyala, S. ^{[1
]}

Barnes, C. N. ^{[1
]}

Borin, M. ^{[1
]}

机构：

[1] Theravance Biopharma US Inc, San Francisco, CA USA

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A3033

引用

页数：1

共 50 条

[21] Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease
Donohue, James F.
Ferguson, Gary T.
Ohar, Jill A.
Lombardi, David A.
Schneider, Roslyn F.
Johnson, Karmon
RESPIRATORY MEDICINE, 2023, 208
[22] Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects
Zhi-Yi Zhang
Jing Wang
Vikram Kansra
Xiaodong Wang
Investigational New Drugs, 2019, 37 : 139 - 146
[23] Revefenacin, a once-daily, long-acting muscarinic antagonist, or nebulized maintenance therapy in patients with chronic obstructive pulmonary disease
Hvisdas, Christopher
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (13) : 1184 - 1194
[24] Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects
Zhang, Zhi-Yi
Wang, Jing
Kansra, Vikram
Wang, Xiaodong
INVESTIGATIONAL NEW DRUGS, 2019, 37 (01) : 139 - 146
[25] COST-EFFECTIVENESS OF FIX-DOSE COMBINATIONS OF LONG-ACTING AGONIST PLUS LONG-ACTING MUSCARINIC ANTAGONIST (LABA/LAMA) FOR THE TREATMENT OF COPD: A SYSTEMATIC REVIEW
Wang, L.
Li, H.
Fu, S.
Zhang, X.
Zhang, D.
Ma, A.
VALUE IN HEALTH, 2020, 23 : S353 - S353
[26] Cost Effectiveness of Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist (ICS/LABA/LAMA) Coverage Related to Reduction in Risk of Exacerbations
White, J.
Szema, A. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
[27] Adherence To Current Guidelines For Chronic Obstructive Pulmonary Disease (COPD) In Subjects Treated With Combination Of Long-Acting Beta2-Agonist (LABA), Long-Acting Muscarinic Antagonist (LAMA) Or Inhaled Corticosteroids (ics)
Asche, C. V.
Leader, S.
Plauschinat, C.
Raparla, S.
Yan, M.
Ye, X.
Young, D.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
[28] ADHERENCE TO CURRENT GUIDELINES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SUBJECTS TREATED WITH COMBINATION OF LONG-ACTING B2-AGONIST (LABA), LONG-ACTING MUSCARINIC ANTAGONIST (LAMA) OR INHALED CORTICOSTEROIDS (ICS)
Asche, C.
Leader, S.
Plauschinat, C.
Raparla, S.
Ye, X.
Yan, M.
Young, D.
VALUE IN HEALTH, 2011, 14 (07) : A492 - A492
[29] Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
Yamada, Hideyasu
Hida, Norihito
Hizawa, Nobuyuki
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 3141 - 3147
[30] COMPARISON OF MONOTHERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST VERSUS COMBINATION THERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST PLUS A LONG-ACTING BETA2-AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Yosuke, Tanaka
Mitsunori, Hino
Naomi, Onda
Hiroyuki, Takoi
Seiji, Kosaihira
Norihisa, Motohashi
Akihiko, Gemma
RESPIROLOGY, 2014, 19 : 122 - 122

← 1 2 3 4 5 →